//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...
Chicago Sports Fan... Nephrologist by day. My tweets are not medical advice. The views expressed here are my own and not those of my employer
Edgar V. Lerma 🇵🇭









Loading...
C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms ca. 2026 @saynanorouzi.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42281853/
Mechanisms by which novel antihypertensive drug classes reduce blood pressure ca. 2025 from @natrevcardiol.nature.com #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/39920248/
Guideline for Prevention, Detection, Evaluation, & Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome ca. 2026 from @americanheart.bsky.social @accintouch.bsky.social @amdiabetesassn.bsky.social @asnkidney.bsky.social #Nephpearls #Cardiorenal #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42265997/
15h
3d
14h
Hemodynamic monitoring in in ICU: Capillary refill time (CRT), is quick, easily performed, and a long-standing component of the physical exam #Nephpearls #AKIinICU #NephSky 👉 pubmed.ncbi.nlm.nih.gov/30772908/ 👉 www.wolterskluwer.com/en/solutions...
Treatment of chronic hyponatremia from Dr Ewout Hoorn #Nephpearls #ERA26 #NephSky
Hyperkalemia and Its Treatment: Real-World Evidence and Managed Care Considerations Supporting Use of Potassium Binders ca. 2026 from @beaverspharmd.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42213908/
Consensus Recommendation: Real World Insights on Attitudes and Treatment of Hyperkalemia ca. 2026 from @garysinger.bsky.social @renalphysicians.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42069178/
Aprocitentan in Patients With CKD and Resistant Hypertension ca. 2026 #Nephpearls #NephSky ✅ Well tolerated ✅ Lowered BP (nighttime ambulatory BP) ✅ Markedly reduced urine albumin-to-creatinine ratio (UACR) in participants w/ CKD and resistant hypertension 👉 pubmed.ncbi.nlm.nih.gov/41363010/
FIND-CKD: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months ca. 2026 from @nejm.org #Nephpearls #ERA26 #NephSky 👉 www.nejm.org/doi/full/10....
Hyperkalemia and Its Treatment: Real-World Evidence and Managed Care Considerations Supporting Use of Potassium Binders ca. 2026 from @beaverspharmd.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42213908/
5d
7d
7d
7d
4d
7d
7d
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭